Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes

Fig. 6

Phyduxon-T, as an immune cell-based regimen, exhibits the characteristics of NK cells, DCs, and TAA-specific CD8 T cells. Phyduxon-T is a novel immune cell-based regimen consisting of the human IKDC counterpart, Phyduxon, and TAA-specific CD8 T cells. Phyduxon demonstrates the ability to eliminate tumor cells and present TAAs, thereby inducing TAA-specific CD8 T-cell responses. The manufacturing protocol of Phyduxon-T facilitates the expansion of TAA-specific T cells, enhancing their potential for tumor destruction. In summary, Phyduxon-T exhibits the characteristics of NK cells, DCs, and T cells, mimicking immunosurveillance and providing a new strategy for adoptive cell transfer therapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us